Our Solution
Market Opportunity
A One Health Opportunity
Veterinary oncology is a ~$1.7B category growing toward ~$5B
One in four dogs develops cancer during their lifetime.
Insights from naturally occurring canine cancer can de-risk and accelerate human drug development

Our Solution
Nebumet: Inhaled Immunotherapy
Nebumet is an investigational, off-the-shelf inhaled immunotherapy for dogs with cancer that has spread, or is likely to spread, to the lungs. It delivers BCG, one of medicine's most established immune stimulants, directly to the airways as a fine mist, using a nebuliser. With multiple patent protections through 2045 and a clear regulatory pathway, Nebumet offers a compelling investment opportunity.
Novel delivery of established immunotherapy with >30 years of human safety data
Proof-of-concept study (NEBULA) in 30 dogs with advanced oral melanoma, alongside a GLP target-animal safety study
Planned route to veterinary market authorisation

Science
The Scientific Foundation
Dogs develop cancer spontaneously, with intact immune systems, and their tumours share key features with human disease. That makes evidence from canine patients directly relevant to human medicine.
Nebumet works by triggering local immune activation in the lungs to combat cancer cells. Our technology is backed by safety and efficacy evidence across multiple species.
Local immune activation by BCG is well documented across species
Mechanism activates the body's immune system against cancer cells
Platform technology expandable to multiple cancer types and species

